Rebecca Taub Sells 2,676 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub sold 2,676 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $245.99, for a total value of $658,269.24. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares of the company’s stock, valued at approximately $112,909,164.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Rebecca Taub also recently made the following trade(s):

• On Wednesday, April 3rd, Rebecca Taub sold 27,845 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $245.14, for a total value of $6,825,923.30.
• On Friday, April 5th, Rebecca Taub sold 27,506 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $243.36, for a total value of $6,693,860.16.

Madrigal Pharmaceuticals Trading Up 0.2 %

Madrigal Pharmaceuticals stock opened at $245.27 on Friday. The stock has a market cap of $4.88 billion, a PE ratio of -12.30 and a beta of -0.47. The stock has a 50-day moving average price of $241.39 and a 200 day moving average price of $206.65. Madrigal Pharmaceuticals, Inc. has a 52 week low of $119.76 and a 52 week high of $322.67. The company has a current ratio of 5.38, a quick ratio of 5.38 and a debt-to-equity ratio of 0.28.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.26) by ($0.42). During the same period in the previous year, the business earned ($4.98) earnings per share. Equities research analysts predict that Madrigal Pharmaceuticals, Inc. will post -21.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MDGL. JMP Securities raised their price target on Madrigal Pharmaceuticals from $351.00 to $397.00 and gave the company an “outperform” rating in a research report on Friday, March 15th. UBS Group raised their price target on Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the company a “buy” rating in a research report on Friday, March 15th. B. Riley upgraded Madrigal Pharmaceuticals from a “sell” rating to a “neutral” rating and raised their price target for the company from $155.00 to $270.00 in a research report on Friday, March 15th. Oppenheimer raised their price target on Madrigal Pharmaceuticals from $320.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, March 15th. Finally, Evercore ISI raised their price target on Madrigal Pharmaceuticals from $325.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, March 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $377.40.

Institutional Trading of Madrigal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in MDGL. Paulson & CO. Inc. boosted its stake in Madrigal Pharmaceuticals by 121.1% in the 4th quarter. Paulson & CO. Inc. now owns 1,105,741 shares of the biopharmaceutical company’s stock worth $255,846,000 after buying an additional 605,741 shares during the last quarter. RTW Investments LP boosted its stake in Madrigal Pharmaceuticals by 163.4% in the 4th quarter. RTW Investments LP now owns 815,191 shares of the biopharmaceutical company’s stock worth $188,619,000 after buying an additional 505,706 shares during the last quarter. Alliancebernstein L.P. boosted its stake in Madrigal Pharmaceuticals by 1,468.0% in the 2nd quarter. Alliancebernstein L.P. now owns 371,116 shares of the biopharmaceutical company’s stock worth $85,728,000 after buying an additional 347,448 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Madrigal Pharmaceuticals in the 1st quarter worth about $33,616,000. Finally, Avoro Capital Advisors LLC lifted its stake in shares of Madrigal Pharmaceuticals by 21.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 1,888,888 shares of the biopharmaceutical company’s stock valued at $437,051,000 after purchasing an additional 333,888 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.